Millendo Therapeutics

$2.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (+6.31%) As of 4:52 PM UTC today

Why Robinhood?

You can buy or sell MLND and other stocks, options, and ETFs commission-free!

About MLND

Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. Its product pipeline includes Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe for classic congenital adrenal hyperplasia; and Neurokinin 3 receptor for vasomotor symptoms. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. The listed name for MLND is Millendo Therapeutics, Inc. Common Stock.

CEO
Louis J. Arcudi, III, MBA
Employees
38
Headquarters
Ann Arbor, Michigan
Founded
2012
Market Cap
41.44M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
604.05K
High Today
$2.20
Low Today
$2.10
Open Price
$2.11
Volume
168.35K
52 Week High
$9.67
52 Week Low
$1.26

MLND Earnings

-$0.87
-$0.58
-$0.29
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

NRACU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure